Related Experiment Video
Updated: Feb 2, 2026

A Pathway Association Study Tool for GWAS Analyses of Metabolic Pathway Information
Published on: July 1, 2020
Association between venous thromboembolism events and fibrates: A comparative study
Charles Dolladille1, Xavier Humbert2, Murielle Faucon3
1Department of pharmacology, CHU de Caen, 14000 Caen, France; Department of cardiology, CHU de Caen, 14000 Caen, France.
Fibrates, particularly fenofibrate, are linked to an increased risk of venous thromboembolism (VTE) events in both diabetic and non-diabetic patients. This finding highlights potential safety concerns for these lipid-lowering drugs.
Area of Science:
- Pharmacovigilance and Pharmacoepidemiology
- Cardiovascular Risk and Thrombosis
- Metabolic Disorders and Drug Safety
Background:
- Previous research indicated a link between fibrates and venous thromboembolism (VTE) in diabetic patients with dyslipidemia, but findings in non-diabetic populations were inconsistent.
- Understanding the association between fibrate use and VTE is crucial for patient safety, especially given their widespread prescription for dyslipidemia.
Purpose of the Study:
- To investigate the association between fibrate medications and the occurrence of VTE events in both diabetic and non-diabetic individuals.
- To compare the risk of VTE associated with fibrate use across different patient populations.
Main Methods:
- A disproportionality analysis was conducted using the World Health Organization VigiBase® pharmacovigilance database to assess the reporting odds ratio (ROR) of VTE events associated with fibrates.
- A case-control study was performed using hospital data, comparing dyslipidemia patients hospitalized for VTE with matched controls hospitalized for non-VTE events.
- Multivariate conditional logistic regression was employed in the case-control study to adjust for potential confounding factors.
Main Results:
- The disproportionality analysis identified a significant association between fibrates and an increased reporting of VTE (ROR 1.14, CI 1.07-1.22).
- The case-control study revealed that fibrates were significantly associated with a higher risk of VTE requiring hospitalization (OR 3.67, CI 1.82-7.37).
- Fenofibrate was specifically identified as the fibrate associated with increased VTE risk in both analytical approaches.
Conclusions:
- Fenofibrate use is associated with a higher incidence of venous thromboembolism events.
- The association between fenofibrate and VTE risk is observed in both diabetic and non-diabetic patients.
- These findings underscore the importance of monitoring for VTE in patients prescribed fenofibrate.
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Return
What is Venous Return?
Venous return refers to the rate at which blood flows back to the heart from the body's peripheral veins. It's an integral part of the circulatory system...
Comparing Mitochondrial, Chloroplast, and Prokaryotic Genomes
Association Areas of the Cortex
Prefrontal Association Area: This area is located in the frontal lobe and is involved in planning, decision-making, and moderating social behavior. It connects with primary motor areas,...
Associative Learning
Classical conditioning, also known...

